ALKS' phase II Vibrance-3 study investigates the safety and efficacy of ALKS 2680 versus placebo for treating adults with idiopathic hypersomnia.

A week after reporting a successful phase 3 trial of Sunosi (solriamfetol) in patients with attention-deficit/hyperactivity ...

Axsome Therapeutics posted mixed results for its experimental depression treatment on Tuesday, leading Axsome stock to dive.

Axsome Therapeutics said Tuesday that a Phase 3 trial for its narcolepsy drug Sunosi failed to meet its primary goal in major ...

Axsome Therapeutics said on Tuesday it will narrow the focus of a late-stage study of its depression drug after an initial ...

Solriamfetol achieved the primary and key secondary endpoint of the Phase III FOCUS trial by significantly lowering attention ...

Axsome Therapeutics said the lower dose of its sleep disorder drug Sunosi met the primary endpoint in a late-stage test of ...

Axsome stock tumbled Tuesday after Axsome Therapeutics issued mixed results for its drug, Sunosi, in ADHD treatment.

Taking a gamble by purchasing the rights to an underperforming narcolepsy drug may soon begin paying dividends for Axsome ...

Axsome Therapeutics' experimental drug to treat attention deficit hyperactivity disorder (ADHD) helped improve symptoms of the developmental disorder in adults, it said on Tuesday, meeting the main ...

Further research revealed that one of these drugs, DDL-920 – developed at UCLA, led to the complete recovery of movement control – something many stroke patients never regain.

Alzheimer's disease is the most common type of dementia. While there's no cure for dementia, medications can help manage or slow down symptoms, including memory loss. Medications may also help control ...